Navigation Links
Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
Date:9/2/2007

WASHINGTON, Sept. 2 /PRNewswire/ -- New data about the safety of drug- eluting stents (DES) translates into excellent news for thousands of patients with cardiovascular disease, according to The Society for Cardiovascular Angiography and Interventions (SCAI). These new findings also underscore the crucial importance of training physicians in the proper selection of patients, proper implantation technique, and in prescribing a strict regimen of medications that prevent blood clots in the first one to two years after DES implantation.

Findings announced this morning from the European Society of Cardiology Congress indicate that patients treated with DES benefit from a 50 percent reduction in restenosis, the re-clogging of arteries that has plagued bare metal stents, with no increased long-term risk. This is in direct contrast to last year's findings based on shorter-term observation of patients from the same registry, which led to widespread concern about whether the devices cause dangerous blood clots and may have dissuaded some patients and their doctors from treatment with DES.

Describing the findings as "reassuring news for patients with cardiovascular disease," SCAI President Bonnie H. Weiner, M.D., FSCAI, Professor of Medicine and Interim Chair of Cardiovascular Medicine at St. Vincent Hospital at Worcester Medical Center in Worcester, MA said, "Patients and physicians have been confused about stents, and we have been concerned that last year's headlines may have prevented some patients from getting the best therapy. This report is consistent with all other data on the benefits of DES and reaffirms the value of drug-eluting stents as a highly effective tool to open blocked arteries and stop regrowth of plaque and scar tissue in those vessels."

After tracking over 13,000 patients for up to 4 years after implantation of stents, Swedish Coronary Angiography and Angiolasty Registry (SCAAR) lead investigator Dr. Stefan James stated that "drug-eluting stents are not dangerous," but he pointed out that in a very small percentage of patients (0.5 percent per year) blood clots may form in these stents. This is in stark contrast to the 50 percent decrease in repeat artery narrowing in DES compared to in that in bare metal stents.

"The SCAAR data represent 'real-world' outcomes that show how Swedish doctors' technique improved over time because of more experience implanting drug-eluting stents resulting in improved outcomes for patients," says SCAI Secretary Steven R. Bailey, M.D., FSCAI, Interim Chief of the Division of Cardiology, Professor of Medicine and Radiology, and Janey Briscoe Distinguished Chair at the University of Texas Health Sciences Center at San Antonio. "Our patients can be reassured by these findings. If their interventional cardiologist chooses to implant a drug-eluting stent, they are receiving a safe and effective treatment."

To explain the new findings, Dr. Weiner points to indications that physicians' technique with the stents has improved and stent patients are now more likely to be on strict regimens of anti-clotting medications for a longer period. SCAI reemphasizes the need for high-quality education and training that will guide physicians in evaluating the benefits and risks of DES for each patient, depending on his or her age, gender, co-morbid conditions, and complexity of disease.

In addition, both physicians and patients need further education on the importance of a strict regimen of both clopidogrel and aspirin, two drugs that help prevent the formation of blood clots. SCAI, a leader in physician education, urges doctors to review the Clinical Alert the Society issued in early 2007 (http://www.scai.org/pdf/DES%20clinical%20alert%20in%20CCI%20Feb07.pdf), which stresses that physicians must take care to use DES in the right patients and the right blood vessels, and only if the patient is willing and able to comply to a long-term regimen of clopidogrel and aspirin.

"SCAI is committed to education and training that helps physicians assess which patients will benefit from drug-eluting stents, use the best implantation technique, and prescribe the right drugs after stent," says Dr. Weiner. "The new SCAAR data re-affirm all the other available results concerning DES, particularly from the clinical trials, showing significant patient benefit and no additional long-term risk."

Headquartered in Washington, DC, the Society for Cardiovascular Angiography and Interventions is a 3,700-member professional organization representing invasive and interventional cardiologists in 70 nations. SCAI's mission is to promote excellence in invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI's annual meeting has become the leading venue for education, discussion, and debate about the latest developments in this dynamic medical specialty.


'/>"/>
SOURCE Society for Cardiovascular Angiography and Interventions
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Abstain from sex- the latest mantra of American teens
2. Doctors operate upon patients in candlelight- latest from the quake scene
3. Vitamin E, the latest warrior against diabetes
4. Latest device for identifying Melanomas
5. Latest discovery on Autism
6. Latest device for cardiac revival under test
7. Latest technique for asthma treatment
8. Latest drug shows promise in multiple myeloma
9. Latest Findings On The Deadly Disease - SARS
10. Latest Tumor Classification More Informative
11. The Latest Preventative Treatment Option for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... Doctor C LLC, a company based out of Arizona that ... continue the marketing and distribution of its product, The Right C. , The Right ... absorption than traditional vitamin C supplements. At the trade show, Doctor C had the ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 ... For Betsy, the clinical trial has been life-saving as she has been on ... , Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy ...
(Date:1/20/2017)... ... ... Chocolate Biscuit”: a biographical account following a man who went on to support his country ... Ivey, born in Lynn Haven, Florida and at the age of 5, his family moved ... he joined the Navy and got married right out of boot camp. , He ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Knowledge is God’s Lighthouse”: a ... “Knowledge is God’s Lighthouse” is the creation of published author, Gene Gaapf, a retired ... collections. , “I have been writing since high school and have many different ...
(Date:1/19/2017)... ... January 19, 2017 , ... Next week after January 20th, ... by Congressional political games that circumvent health needs of over 30 million. Many interviews ... human anxieties and needs government public servants were suppose to prioritize. Interviews provided below. ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... , Jan. 20, 2017  Ethicon Endo-Surgery, ... Megadyne Medical Products, Inc., a privately held ... markets electrosurgical tools used in operating rooms ... of Ethicon,s* advanced energy devices with Megadyne,s ... major step forward in Ethicon,s goal to ...
(Date:1/20/2017)... 20, 2017  Palladian Health, a leading provider ... launch of an opioid management program which assists ... and helps stem the growing tide of dependence ... treat chronic non-cancer pain (back pain, neck pain, ... lack of evidence regarding long-term effectiveness. ...
(Date:1/20/2017)... , January 20, 2017 Avillion LLP, ... appointment of Mark Weinberg , MD MBA as Chief Medical ... , USA . ... Dr Weinberg has spent more than 17 years ... 20" pharma companies to micro-cap biotech. Over the course of his ...
Breaking Medicine Technology: